59.65
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bio Techne Corp stock is traded at $59.65, with a volume of 1.94M.
It is up +1.43% in the last 24 hours and down -5.24% over the past month.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$58.81
Open:
$58.81
24h Volume:
1.94M
Relative Volume:
0.99
Market Cap:
$9.29B
Revenue:
$1.17B
Net Income/Loss:
$150.71M
P/E Ratio:
63.46
EPS:
0.94
Net Cash Flow:
$245.03M
1W Performance:
+0.73%
1M Performance:
-5.24%
6M Performance:
+12.17%
1Y Performance:
-16.55%
Bio Techne Corp Stock (TECH) Company Profile
Name
Bio Techne Corp
Sector
Industry
Phone
612-379-8854
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Compare TECH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
TECH
Bio Techne Corp
|
59.65 | 9.16B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-21-25 | Upgrade | Citigroup | Neutral → Buy |
| Jul-22-25 | Resumed | Stephens | Overweight |
| Jul-09-25 | Initiated | TD Cowen | Buy |
| May-30-25 | Initiated | Wells Fargo | Overweight |
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-18-25 | Initiated | Evercore ISI | Outperform |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-08-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-02-24 | Downgrade | Stifel | Buy → Hold |
| Dec-07-23 | Initiated | UBS | Buy |
| Aug-28-23 | Initiated | William Blair | Outperform |
| Jan-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-12-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Sep-15-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Mar-08-21 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-23-21 | Upgrade | Stifel | Hold → Buy |
| Jan-25-21 | Reiterated | The Benchmark Company | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Jul-15-20 | Downgrade | Stephens | Overweight → Equal-Weight |
| May-27-20 | Downgrade | Stifel | Buy → Hold |
| May-14-20 | Initiated | The Benchmark Company | Buy |
| Jan-08-20 | Resumed | Stephens | Overweight |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Nov-15-19 | Initiated | Stifel | Buy |
| Jul-02-19 | Upgrade | Janney | Neutral → Buy |
| Jan-14-19 | Upgrade | Stephens | Equal-Weight → Overweight |
| Oct-31-18 | Downgrade | Craig Hallum | Buy → Hold |
| Oct-17-18 | Initiated | Goldman | Neutral |
| Jun-15-18 | Initiated | Argus | Buy |
| Jul-13-17 | Initiated | Wells Fargo | Market Perform |
| Feb-09-17 | Initiated | Citigroup | Buy |
| Jan-18-17 | Initiated | Deutsche Bank | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Jan-21-15 | Reiterated | Robert W. Baird | Outperform |
| Sep-20-13 | Upgrade | Robert W. Baird | Neutral → Outperform |
View All
Bio Techne Corp Stock (TECH) Latest News
Fort Washington Investment Advisors Inc. OH Buys 35,165 Shares of Bio-Techne Corp $TECH - MarketBeat
Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH) - Yahoo Finance
Bio-Techne Corp (TECH) Stock Price History & Data - Traders Union
Voya Investment Management LLC Has $7.04 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Assenagon Asset Management S.A. Invests $2.75 Million in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference - Investing News Network
Bio-Techne (TECH): Revisiting Valuation as Recent Gains Contrast a Weak One-Year Shareholder Return - Yahoo Finance
Bio-Techne Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Riverbridge Partners LLC Trims Stock Position in Bio-Techne Corp $TECH - MarketBeat
Will Bio Techne Corporation stock gain from strong economyMarket Rally & Free Low Drawdown Momentum Trade Ideas - Улправда
Why Bio Techne Corporation stock appeals to analystsJuly 2025 Momentum & Capital Protection Trade Alerts - Улправда
Will New 3D Multiomic Workflow and Leo System Expansion Change Bio-Techne's (TECH) Narrative? - simplywall.st
Bio-Techne Corp. stock outperforms competitors on strong trading day - MarketWatch
How Bio Techne Corporation stock compares to industry benchmarksJuly 2025 Rallies & Free Weekly Watchlist of Top Performers - DonanımHaber
Bio-Techne (NASDAQ:TECH) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
Trading Action: Will Bio Techne Corporation stock gain from strong economyMarket Volume Summary & Technical Pattern Based Buy Signals - Улправда
Thrivent Financial for Lutherans Has $11.53 Million Holdings in Bio-Techne Corp $TECH - MarketBeat
Corient Private Wealth LLC Reduces Stake in Bio-Techne Corp $TECH - MarketBeat
Aaron Wealth Advisors LLC Takes $980,000 Position in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Palmetto Grain Brokerage - Palmetto Grain Brokerage
Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector? - Barchart.com
Neuberger Berman Group LLC Has $128.62 Million Stake in Bio-Techne Corp $TECH - MarketBeat
Reassessing Bio-Techne (TECH) Valuation After a Weak Year and Recent Share Price Rebound - simplywall.st
Bamco Inc. NY Has $143.81 Million Stake in Bio-Techne Corp $TECH - MarketBeat
4D Advisors LLC Makes New $2.06 Million Investment in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
GMP Cytokine Market and Competition Outlook to 2031: Growing at 8.4% CAGR, Led by Bio-Techne, PeproTech, CellGenix Among OthersResearchAndMarkets.com - The AI Journal
Osterweis Capital Management Inc. Has $7.70 Million Stake in Bio-Techne Corp $TECH - MarketBeat
Cerity Partners LLC Boosts Stake in Bio-Techne Corp $TECH - MarketBeat
Check out Bio-Techne Corp's stock price (1TECH-IT) in real time - CNBC
Here’s Why BioTechne (TECH) Traded Lower in Q3 - Yahoo Finance
Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology - Investing News Network
Bio-techne and Wyss Center partner to develop automated 3D multiomics - Investing.com
Bio-Techne (NASDAQ: TECH) and Wyss Geneva to develop automated 3D multiomics workflow - Stock Titan
Amundi Buys 19,844 Shares of Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Stake Lessened by SVB Wealth LLC - MarketBeat
Bio-Techne Corp (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Does Bio-Techne’s Recent Weakness Offer an Opportunity After Its Cell and Gene Therapy Push? - Yahoo Finance
Bio-Techne Announces Expanded Launch Of Next-Generation Leo System - Nasdaq
Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis - Investing News Network
Bio-techne ships enhanced Leo System with expanded detection capabilities - Investing.com
Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence - Stock Titan
Transcript : Bio-Techne Corporation Presents at 53rd Annual Nasdaq Investor Conference, Dec-09-2025 09 - marketscreener.com
Bio-Techne Corp. stock outperforms competitors despite losses on the day - MarketWatch
WINTON GROUP Ltd Makes New $6.23 Million Investment in Bio-Techne Corp $TECH - MarketBeat
Bio-Techne Corp $TECH Shares Sold by Invesco Ltd. - MarketBeat
Arrowstreet Capital Limited Partnership Has $18.94 Million Stake in Bio-Techne Corp $TECH - MarketBeat
Quantbot Technologies LP Purchases New Stake in Bio-Techne Corp $TECH - MarketBeat
Baird Financial Group Inc. Has $29.11 Million Stock Holdings in Bio-Techne Corp $TECH - MarketBeat
Cresset Asset Management LLC Boosts Holdings in Bio-Techne Corp $TECH - MarketBeat
Bio Techne Corp Stock (TECH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bio Techne Corp Stock (TECH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Geist William | PRESIDENT, PROTEIN SCIENCES |
Nov 03 '25 |
Option Exercise |
0.00 |
9,911 |
0 |
25,023 |
| Nusse Roeland | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,599 |
| Nusse Roeland | Director |
Aug 25 '25 |
Sale |
56.36 |
17,040 |
960,388 |
44,559 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Option Exercise |
21.84 |
17,040 |
372,154 |
61,903 |
| BAUMGARTNER ROBERT V | Director |
Aug 25 '25 |
Sale |
56.21 |
17,040 |
957,818 |
44,863 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):